Lilly GMP Strategy: Avoid Consent Degree With Open Communication At FDA

Lilly's ongoing, "open" communication with FDA over good manufacturing practices should help avoid a consent decree, CFO Charles Golden said during the Bear Stearns healthcare conference in New York Sept. 19

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet